New Report
Biotechnology and Pharmaceuticals Report
April 04, 2011
3 leading Analysts; and top management from 5 Sector Firms examine this vital industry
» See all the topics and companies covered
-
Defensive Vs. Offensive Strategies In Pharma/biotech - Michael Yee - Rbc Capital Markets
Michael Yee - Rbc Capital Markets
-
The Biotech Industry Amid A Major Product Cycle - Ian Somaiya - Piper Jaffray & Co.
Ian Somaiya - Piper Jaffray & Co.
-
Investing In Small- & Midcap Biotech Companies - Dr. Jason Kantor - Rbc Capital Markets
Dr. Jason Kantor - Rbc Capital Markets
-
Trius Therapeutics - Dr. Jeffrey Stein, Ph.d.
Dr. Jeffrey Stein, Ph.d.
-
Depomed, Inc. - Carl Pelzel
Carl Pelzel
-
Optimer Pharmaceuticals, Inc. - Pedro Lichtinger
Pedro Lichtinger
-
Oncogenex Pharmaceuticals, Inc. - Scott Cormack
Scott Cormack
-
Telik, Inc. - Dr. Michael M. Wick, M.d., Ph.d.
Dr. Michael M. Wick, M.d., Ph.d.










